Gordon Wishart

Last updated

Professor Gordon C Wishart
Born (1960-09-03) 3 September 1960 (age 64)
Edinburgh, Scotland
Nationality Scottish
Alma mater University of Edinburgh
Known forDiagnosis and treatment of breast cancer, development of Predict cancer survival model, founder of Check4Cancer Ltd
Scientific career
Fields Medicine, oncology, surgical oncology
Institutions Royal College of Surgeons of Glasgow, Royal College of Surgeons of England, Addenbrooke’s Hospital, Cambridge, University of Cambridge, Anglia Ruskin School of Medicine

Professor Gordon C. Wishart FRCS (Eng.) FRCS (Gen.) (3 September 1960-) is the founder, Chief Medical Officer, and CEO of Check4Cancer, an early cancer detection and prevention organisation . In 2016, Check4Cancer launched rapid access, streamlined, and audited diagnostic pathways for breast and skin cancer for the insured and self-pay markets, leading to the award of “Diagnostic Provider of the Year” at the annual Health Investor Awards in 2018. In late 2017, Check4Cancer launched the first worldwide breast cancer risk test (MyBreastRisk) to combine genetic, family history, and lifestyle risk factors to underpin a risk-stratified breast screening programme.

Contents

As the former Director of the Cambridge Breast Unit from 2005-2010, and current Professor of Cancer Surgery at Anglia Ruskin School of Medicine since 2008, he has contributed to clinical research and modernisation of cancer diagnosis and treatment, with more than 100 peer-reviewed papers in scientific journals. In 2010, he led a team of clinicians and scientists that developed the PREDICT breast cancer treatment and survival model, which is now used worldwide.

Early life and education

Gordon Cranston Wishart was born in Edinburgh, Scotland, on 3 September 1960.[ citation needed ]

He studied at the University of Edinburgh Medical School, where he received his MB ChB in July 1983. He subsequently obtained his MD from the University of Edinburgh in June 1992 with a thesis entitled Aspects of multidrug resistance in breast cancer. [1]

Research and publications

Wishart is notable for his prolific clinical research output, alongside his work as a practising breast and endocrine surgeon.

He has received the following prizes as recognition for his scientific contribution:

As of October 2009, he is principal investigator on the following studies:

In addition, he is a co-investigator, surgical coordinator, or clinical surgical coordinator on an additional 15 research studies. [5]

His research has been published in The Lancet, [6] the British Journal of Cancer, [7] [8] [9] [10] [11] the British Medical Journal, [12] the Journal of Clinical Oncology, [13] and the British Journal of Surgery. [14] [15]

Major achievements

Current posts

Gordon Wishart currently holds the following posts:

He also acts as a referee for the British Journal of Surgery, the European Journal of Surgical Oncology, and Nuclear Medicine Communications.[ citation needed ]

Related Research Articles

<span class="mw-page-title-main">Mastectomy</span> Surgical removal of one or both breasts

Mastectomy is the medical term for the surgical removal of one or both breasts, partially or completely. A mastectomy is usually carried out to treat breast cancer. In some cases, women believed to be at high risk of breast cancer have the operation as a preventive measure. Alternatively, some women can choose to have a wide local excision, also known as a lumpectomy, an operation in which a small volume of breast tissue containing the tumor and a surrounding margin of healthy tissue is removed to conserve the breast. Both mastectomy and lumpectomy are referred to as "local therapies" for breast cancer, targeting the area of the tumor, as opposed to systemic therapies, such as chemotherapy, hormonal therapy, or immunotherapy.

<span class="mw-page-title-main">Breast cancer</span> Cancer that originates in mammary glands

Breast cancer is a cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a red or scaly patch of skin. In those with distant spread of the disease, there may be bone pain, swollen lymph nodes, shortness of breath, or yellow skin.

Technetium (<sup>99m</sup>Tc) sestamibi Pharmaceutical drug

Technetium (99mTc) sestamibi (INN) is a pharmaceutical agent used in nuclear medicine imaging. The drug is a coordination complex consisting of the radioisotope technetium-99m bound to six (sesta=6) methoxyisobutylisonitrile (MIBI) ligands. The anion is not defined. The generic drug became available late September 2008. A scan of a patient using MIBI is commonly known as a "MIBI scan".

<span class="mw-page-title-main">Parathyroidectomy</span> Surgical removal of one or more of the parathyroid glands

Parathyroidectomy is the surgical removal of one or more of the (usually) four parathyroid glands. This procedure is used to remove an adenoma or hyperplasia of these glands when they are producing excessive parathyroid hormone (PTH): hyperparathyroidism. The glands are usually four in number and located adjacent to the posterior surface of the thyroid gland, but their exact location is variable. When an elevated PTH level is found, a sestamibi scan or an ultrasound may be performed in order to confirm the presence and location of abnormal parathyroid tissue.

Cancer staging is the process of determining the extent to which a cancer has grown and spread. A number from I to IV is assigned, with I being an isolated cancer and IV being a cancer that has metastasized and spread from its origin. The stage generally takes into account the size of a tumor, whether it has invaded adjacent organs, how many regional (nearby) lymph nodes it has spread to, and whether it has appeared in more distant locations (metastasized).

This is a list of terms related to oncology. The original source for this list was the US National Cancer Institute's public domain Dictionary of Cancer Terms.

<span class="mw-page-title-main">Lymphadenectomy</span> Surgical removal of lymph nodes

Lymphadenectomy, or lymph node dissection, is the surgical removal of one or more groups of lymph nodes. It is almost always performed as part of the surgical management of cancer. In a regional lymph node dissection, some of the lymph nodes in the tumor area are removed; in a radical lymph node dissection, most or all of the lymph nodes in the tumor area are removed.

<span class="mw-page-title-main">Lumpectomy</span> Limited surgical removal of breast tissue

Lumpectomy is a surgical removal of a discrete portion or "lump" of breast tissue, usually in the treatment of a malignant tumor or breast cancer. It is considered a viable breast conservation therapy, as the amount of tissue removed is limited compared to a full-breast mastectomy, and thus may have physical and emotional advantages over more disfiguring treatment. Sometimes a lumpectomy may be used to either confirm or rule out that cancer has actually been detected. A lumpectomy is usually recommended to patients whose cancer has been detected early and who do not have enlarged tumors. Although a lumpectomy is used to allow for most of the breast to remain intact, the procedure may result in adverse affects that can include sensitivity and result in scar tissue, pain, and possible disfiguration of the breast if the lump taken out is significant. According to National Comprehensive Cancer Network guidelines, lumpectomy may be performed for ductal carcinoma in situ (DCIS), invasive ductal carcinoma, or other conditions.

<span class="mw-page-title-main">Sentinel lymph node</span> First lymph node to receive drainage from a primary tumor

The sentinel lymph node is the hypothetical first lymph node or group of nodes draining a cancer. In case of established cancerous dissemination it is postulated that the sentinel lymph nodes are the target organs primarily reached by metastasizing cancer cells from the tumor.

MammaPrint is a prognostic and predictive diagnostic test for early stage breast cancer patients that assess the risk that a tumor will metastasize to other parts of the body. It gives a binary result, high-risk or low-risk classification, and helps physicians determine whether or not a patient will benefit from chemotherapy. Women with a low risk result can safely forego chemotherapy without decreasing likelihood of disease free survival. MammaPrint is part of the personalized medicine portfolio marketed by Agendia.

<span class="mw-page-title-main">Radical mastectomy</span> Removal of cancerous breast

Radical mastectomy is a surgical procedure that treats breast cancer by removing the breast and its underlying chest muscle, and lymph nodes of the axilla (armpit). Breast cancer is the most common cancer among women. During the early twentieth century it was primarily treated by surgery, when the mastectomy was developed. However, with the advancement of technology and surgical skills in recent years, mastectomies have become less invasive. As of 2016, a combination of radiotherapy and breast conserving mastectomy are considered optimal treatment.

<span class="mw-page-title-main">Papillary thyroid cancer</span> Medical condition

Papillary thyroid cancer is the most common type of thyroid cancer, representing 75 percent to 85 percent of all thyroid cancer cases. It occurs more frequently in women and presents in the 20–55 year age group. It is also the predominant cancer type in children with thyroid cancer, and in patients with thyroid cancer who have had previous radiation to the head and neck. It is often well-differentiated, slow-growing, and localized, although it can metastasize.

<span class="mw-page-title-main">Axillary lymph nodes</span> Lymph nodes in the human armpit

The axillary lymph nodes or armpit lymph nodes are lymph nodes in the human armpit. Between 20 and 49 in number, they drain lymph vessels from the lateral quadrants of the breast, the superficial lymph vessels from thin walls of the chest and the abdomen above the level of the navel, and the vessels from the upper limb. They are divided in several groups according to their location in the armpit. These lymph nodes are clinically significant in breast cancer, and metastases from the breast to the axillary lymph nodes are considered in the staging of the disease.

Breast cancer management takes different approaches depending on physical and biological characteristics of the disease, as well as the age, over-all health and personal preferences of the patient. Treatment types can be classified into local therapy and systemic treatment. Local therapy is most efficacious in early stage breast cancer, while systemic therapy is generally justified in advanced and metastatic disease, or in diseases with specific phenotypes.

<span class="mw-page-title-main">Breast-conserving surgery</span> Surgical operation

Breast-conserving surgery refers to an operation that aims to remove breast cancer while avoiding a mastectomy. Different forms of this operation include: lumpectomy (tylectomy), wide local excision, segmental resection, and quadrantectomy. Breast-conserving surgery has been increasingly accepted as an alternative to mastectomy in specific patients, as it provides tumor removal while maintaining an acceptable cosmetic outcome. This page reviews the history of this operation, important considerations in decision making and patient selection, and the emerging field of oncoplastic breast conservation surgery.

Cancer of unknown primary origin (CUP) is a cancer that is determined to be at the metastatic stage at the time of diagnosis, but a primary tumor cannot be identified. A diagnosis of CUP requires a clinical picture consistent with metastatic disease and one or more biopsy results inconsistent with a tumor cancer

<span class="mw-page-title-main">Medullary thyroid cancer</span> Malignant thyroid neoplasm originating from C-cells

Medullary thyroid cancer is a form of thyroid carcinoma which originates from the parafollicular cells, which produce the hormone calcitonin. Medullary tumors are the third most common of all thyroid cancers and together make up about 3% of all thyroid cancer cases. MTC was first characterized in 1959.

<span class="mw-page-title-main">Targeted intra-operative radiotherapy</span> Method of targeted radiotherapy after surgical removal of tumours

Targeted intra-operative radiotherapy, also known as targeted IORT, is a technique of giving radiotherapy to the tissues surrounding a cancer after its surgical removal, a form of intraoperative radiation therapy. The technique was designed in 1998 at the University College London.

Anne Louise Rosenberg is an American surgical oncologist retired from practice in Cherry Hill, New Jersey.

<span class="mw-page-title-main">Armando E. Giuliano</span> American surgical oncologist

Armando Elario Giuliano is a surgical oncologist, surgeon scientist and medical professor in Los Angeles, California, United States of America. He is the Linda and Jim Lippman Chair in Surgical Oncology and co-director of Saul and Joyce Brandman Breast Center at Cedars-Sinai Medical Center, Los Angeles.

References

  1. Wishart, Gordon (1992). "Aspects of multidrug resistance in breast cancer". hdl:1842/20307.{{cite journal}}: Cite journal requires |journal= (help)
  2. "Select My Surgeon - Gordon Wishart Profile". Archived from the original on 16 July 2011. Retrieved 28 October 2009.
  3. Wiley Interscience
  4. http://www.baes.info/Pages/newsletter_November_2007.pdf British Association of Endocrine and Thyroid Surgeons, Newsletter, November 2007
  5. Gordon Wishart’s CV on Select My Surgeon [ permanent dead link ]
  6. The importance, availability and measurement of oestrogen receptor (ER) status in the management of breast cancer in the United Kingdom – results of a nationwide survey. BJ Mander, K Heal, AD Purushotham, GC Wishart. The Lancet 1998; 352: 36-37
  7. GC Wishart, JA Plumb, JJ Going, AM McNicol, CS McArdle, T Tsuruo, SB Kaye. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990; 62: 758-761
  8. T Barrett, D J Bowden, D C Greenberg, C H Brown, G C Wishart, P D Britton. Radiological staging in breast cancer: which asymptomatic patients to image and how. British Journal of Cancer, 29 September 2009
  9. S J Dawson, S W Duffy, F M Blows, K E Driver, E Provenzano, J LeQuesne, D C Greenberg, P Pharoah, C Caldas, G C Wishart. Molecular characteristics of screen-detected vs symptomatic breast cancers and their impact on survival. Br J Cancer 2009; 101: 1338-1344
  10. L Hughes-Davies, C Caldas, G C Wishart. Tamoxifen: the drug that came in from the cold. British Journal of Cancer 2009; 101: 875-878
  11. G C Wishart, D C Greenberg, P D Britton, P Chou, C H Brown, A D Purushotham, S W Duffy. Screen-detected vs symptomatic breast cancer: is improved survival due to stage migration alone? British Journal of Cancer 2008; 98: 1741-1744
  12. BJ Mander, GH Cunnick, M Daultrey, GC Wishart. Medical and psychological effects of early discharge after surgery for breast cancer. BMJ 1998; 317: 1081-1082
  13. GC Wishart, D Bissett, J Paul, D Jodrell, A Harnett, T Habeshaw, DJ Kerr, MA Macham, M Soukop, RC Leonard. Quinidine as a resistance modulator of epirubicin in advanced breast cancer: mature results of a placebo-controlled randomized trial J Clin Oncol, 1 September 1994: 1771-1777
  14. Gurnell E.M., Thomas S.K., McFarlane I., Munday I., Balan K.K., Berman L., Chatterjee V.K.K., Wishart G.C. Focused parathyroid surgery with intraoperative parathyroid hormone measurement as a day-case procedure. British Journal of Surgery 2004, 91(1), pp. 78-82
  15. Gupta, Y, Ahmed, R, Happerfield, L, Pinder, SE, Balan, KK, Wishart, GC. P-glycoprotein expression is associated with sestamibi washout in primary hyperparathyroidism. British Journal of Surgery, 2007. 94(12) pp. 1491-1495
  16. GC Wishart, JA Plumb, JJ Going, AM McNicol, CS McArdle, T Tsuruo, SB Kaye. P-glycoprotein expression in primary breast cancer detected by immunocytochemistry with two monoclonal antibodies. Br J Cancer 1990; 62: 758-761
  17. BJ Mander, GH Cunnick, M Daultrey, GC Wishart. Medical and psychological effects of early discharge after surgery for breast cancer. BMJ 1998; 317: 1081-1082
  18. Gurnell EM, Thomas SK, McFarlane I, Munday I, Balan KK, Berman L, Chatterjee VKK, Wishart GC. Focused parathyroid surgery with intraoperative parathyroid hormone measurement as a day-case procedure. British Journal of Surgery 2004, 91(1), pp. 78-82
  19. Gold Seed Study: Evaluation of Tumour Bed Localisation and Image-guided Radiotherapy for Breast Cancer. On Behalf Of The Import Working Party, Coles CE, Wishart G, Donovan E, Harris E, Poynter A, Twyman N, Routsis D, Wilkinson J, Yarnold J. Clin Oncol (R Coll Radiol). 2007 Apr;19(3):S26-7.
  20. Britton PD, Goud A, Godward S, Barter S, Freeman A, Gaskarth M, Rajan P, Sinnatamby R, Slattery J, Provenzano E, O’Donovan M, Pinder S , Benson J, Forouhi P, Wishart GC. Use of ultrasound-guided axillary node core biopsy in staging of early breast cancer. European Radiology 2009; 19: 561-569
  21. Britton P D, Provenzano E, Barter S, Gaskarth M, Goud A, Moyle P, Sinnatamby R, Wallis M, Benson J R, Forouhi P, Wishart GC. Ultrasound-guided percutaneous axillary lymph node core biopsy: how often is the sentinel lymph node being biopsied? The Breast 2009; 18(1): 13-16.
  22. Breast Cancer Risk for Daughters
  23. Anglia Ruskin University – Pink Rose Appeal
  24. University of Cambridge – Graces to be submitted to the Regent House at a Congregation on 22 July 2006